Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis

Journal of Cardiac Failure

Volumn 20, Issue 7, 2014, Pages 522-532

  Hopper, Ingrid ^a,b   Samuel, Rohit ^a   Hayward, Christopher ^c   Tonkin, Andrew ^a   Krum, Henry ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b Alfred Health ^*  (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

digoxin; Medication discontinuation; peripartum cardiomyopathy; polypharmacy

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; LISINOPRIL; METOPROLOL; NITRIC ACID DERIVATIVE; PLACEBO; QUINAPRIL; VASODILATOR AGENT; WARFARIN; CARDIOVASCULAR AGENT;

ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONVALESCENCE; DIURETIC THERAPY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEART FAILURE; HOSPITALIZATION; HUMAN; MEDICAL ETHICS; META ANALYSIS; PERIPARTUM CARDIOMYOPATHY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CHRONIC DISEASE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBSTANCE WITHDRAWAL SYNDROME;

CARDIOVASCULAR AGENTS; CHRONIC DISEASE; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84903823167     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.04.013     Document Type: Review

References (75)

1. C. Wong, S. Chaudhry, M. Desai, and H. Krumholz Trends in comorbidity, disability, and polypharmacy in heart failure Am J Med 124 2011 136 143
2. S.M. Dunlay, J.M. Eveleth, N.D. Shah, S.M. McNallan, and V.L. Roger Medication adherence among community-dwelling patients with heart failure Mayo Clin Proc 86 2011 273 281
3. E. Caughey, E. Roughead, S. Shakib, A. Vitry, and A. Gilbert Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, cross-sectional study of administrative claims data Drugs Aging 28 2011 575 581
4. K.K. Viktil, H.S. Blix, T.A. Moger, and A. Reikvam Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems Br J Clin Pharmacol 63 2007 187 195
5. S.M. Vardan, and C.M. Pratt Combination drug therapy in patients with heart failure: tenets of rational polypharmacy Cardiol Rev 6 1998 267 271
6. G.S. Francis, and J.B. Young The looming polypharmacy crisis in the management of patients with heart failure. Potential solutions Cardiol Clin 19 2001 541 545
7. B. Straubhaar, S. Krahenbuhl, and R.G. Schlienger The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge Drug Saf 29 2006 79 90
8. L.R. Punnoose, M.M. Givertz, E.F. Lewis, P. Pratibhu, L.W. Stevenson, and A.S. Desai Heart failure with recovered ejection fraction: a distinct clinical entity J Card Fail 17 2011 527 532
9. P.F. Binkley A new era in the natural history of dilated cardiomyopathy J Am Coll Cardiol 59 2012 776 author reply-7
10. U. Elkayam Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management J Am Coll Cardiol 58 2011 659 670
11. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
12. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, and K. Dickstein et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 14 2012 803 869
13. Review Manager (Revman) [Computer program]. Version 5.2 2012 Nordic Cochrane Centre TCC Copenhagen
14. J.A. Sterne, A.J. Sutton, J.P. Ioannidis, N. Terrin, D.R. Jones, and J. Lau et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials BMJ 343 2011 d4002
15. R. de Silva, N.P. Nikitin, K.K. Witte, A.S. Rigby, H. Loh, and A. Nicholson et al. Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure Eur J Heart Fail 9 2007 415 423
16. M.G. Nicholls, H. Ikram, E.A. Espiner, A.H. Maslowski, M.S. Scandrett, and T. Penman Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies Am J Cardiol 49 1982 1497 1501
17. A.H. Maslowski, M.G. Nicholls, H. Ikram, E.A. Espiner, and J.G. Turner Haemodynamic, hormonal, and electrolyte responses to withdrawal of long-term captopril treatment for heart failure 2 1981 959 961
18. P.W. Pflugfelder, M.G. Baird, M.J. Tonkon, R. DiBianco, B. Pitt Quinapril Heart Failure Trial Investigators Clinical consequences of angiotensin- converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril J Am Coll Cardiol 22 1993 1557 1563
19. W.J. Remme, G. Riegger, P. Hildebrandt, M. Komajda, W. Jaarsma, and M. Bobbio et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN) Cardiovasc Drugs Ther 18 2004 57 66
20. K. Swedberg, A. Hjalmarson, F. Waagstein, and I. Wallentin Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy Br Heart J 44 1980 134 142
21. F. Waagstein, K. Caidahl, I. Wallentin, C.H. Bergh, and A. Hjalmarson Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol 80 1989 551 563
22. S. Morimoto, K. Shimizu, K. Yamada, S. Hiramitsu, and H. Hishida Can β-blocker therapy be withdrawn from patients with dilated cardiomyopathy Am Heart J 138 1999 456 459
23. J. Moon, Y.-G. Ko, N. Chung, J.-W. Ha, S.-M. Kang, and E.-Y. Choi et al. Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy Can J Cardiol 25 2009 e147 e150
24. A.M. Amos, W.A. Jaber, and S.D. Russell Improved outcomes in peripartum cardiomyopathy with contemporary Am Heart J 152 2006 509 513
25. P. Poole-Wilson, and K. Robsinson Digoxin - a redundant drug in congestive cardiac failure Cardiovasc Drugs Ther 2 1989 733 741
26. B.F. Uretsky, J.B. Young, F.E. Shahidi, L.G. Yellen, M.C. Harrison, M.K. Jolly PROVED Investigative Group Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial J Am Coll Cardiol 22 1993 955 962
27. M. Packer, M. Gheorghiade, J.B. Young, P.J. Costantini, K.F. Adams, and R.J. Cody et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study N Engl J Med 329 1993 1 7
28. K.F. Adams Jr., M. Gheorghiade, B.F. Uretsky, J.B. Young, S. Ahmed, and L. Tomasko et al. Patients with mild heart failure worsen during withdrawal from digoxin therapy J Am Coll Cardiol 30 1997 42 48
29. K.F. Adams, M. Gheorghiade, B.F. Uretsky, J.B. Young, J.H. Patterson, and L. Tomasko et al. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy Am Heart J 135 1998 389 397
30. A. Ahmed, G. Gambassi, M.T. Weaver, J.B. Young, W.H. Wehrmacher, and M.W. Rich Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure Am J Cardiol 100 2007 280 284
31. Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 1997 525 533
32. J.L. Fleg, S.H. Gottlieb, and E.G. Lakatta Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm Am J Med 73 1982 244 250
33. G.H. Guyatt, M.J. Sullivan, E.L. Fallen, H. Tihal, E. Rideout, and S. Halcrow et al. A controlled trial of digoxin in congestive heart failure Am J Cardiol 61 1988 371 375
34. D.C. Lee, R.A. Johnson, J.B. Bingham, M. Leahy, R.E. Dinsmore, and A.H. Goroll et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo N Engl J Med 306 1982 699 705
35. A.J. Taggart, G.D. Johnston, and D.G. McDevitt Digoxin withdrawal after cardiac failure in patients with sinus rhythm J Cardiovasc Pharmacol 5 1983 229 234
36. N.W. Shammas, M.L. Harris, D. McKinney, and W.J. Hauber Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers Clin Cardiol 24 2001 786 787
37. A.U. Khand, A.C. Rankin, W. Martin, J. Taylor, I. Gemmell, and J.G. Cleland Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42 2003 1944 1951
38. I.C. Van Gelder, H.F. Groenveld, H.J. Crijns, Y.S. Tuininga, J.G. Tijssen, and A.M. Alings et al. Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med 362 2010 1363 1373
39. M. Rienstra, K. Damman, B.A. Mulder, I.C. Van Gelder, J.J. McMurray, and D.J. Van Veldhuisen Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis JACC Heart fail 1 2013 21 28
40. J. Bayliss, M. Norell, R. Canepa-Anson, G. Sutton, and P. Poole-Wilson Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics Br Heart J 57 1987 17 22
41. G.S. Francis, C. Benedict, D.E. Johnstone, P.C. Kirlin, J. Nicklas, and C.S. Liang et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 82 1990 1724 1729
42. T.G. von Lueder, D. Atar, and H. Krum Diuretic use in heart failure and outcomes Clin Pharmacol Ther 94 2013 490 498
43. A. Richardson, J. Bayliss, A.J. Scriven, J. Parameshwar, P.A. Poole-Wilson, and G.C. Sutton Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure 2 1987 709 711
44. W.C. Grinstead, M.J. Francis, G.F. Marks, C.B. Tawa, W.A. Zoghbi, and J.B. Young Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy Am J Cardiol 73 1994 881 886
45. B. Magnani Converting enzyme inhibition and heart failure Am J Med 84 1988 87 91
46. E.P. Walma, A.W. Hoes, C. van Dooren, A. Prins, and E. van der Does Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial BMJ 315 1997 464 468
47. E. Galve, A. Mallol, R. Catalan, J. Palet, S. Mendez, and E. Nieto et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction Eur J Heart Fail 7 2005 892 898
48. F. Braunschweig, C. Linde, M.J. Eriksson, C. Hofman-Bang, and L. Ryden Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure Eur Heart J 23 2002 59 69
49. S. Wieshammer, M. Hetzel, J. Hetzel, E. Henze, and V. Hombach Effects of chronic nitrate therapy on left-ventricular volume in patients with heart failure secondary to coronary disease already treated with captopril: a withdrawal study Cardiology 95 2001 61 65
50. SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
51. J.G. Cleland, I. Findlay, S. Jafri, G. Sutton, R. Falk, and C. Bulpitt et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure Am Heart J 148 2004 157 164
52. L. Tavazzi, A.P. Maggioni, R. Marchioli, S. Barlera, M.G. Franzosi, and R. Latini et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
53. J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J.G. Cleland, and J.H. Cornel et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261
54. U. Elkayam, P.P. Tummala, K. Rao, M.W. Akhter, I.S. Karaalp, and O.R. Wani et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy N Engl J Med 344 2001 1567 1571 [Erratum appears in N Engl J Med 2001;345:552]
55. P.A. Poole-Wilson Digoxin withdrawal in patients with heart failure J Am Coll Cardiol 24 1994 578 579
56. J.G.F. Cleland, and D. Cullington Digoxin: quo vadis? Circ Heart Fail 2 2009 81 85
57. A. Ahmed, M. Rich, T. Love, D. Lloyd-Jones, I. Aban, and W. Colucci et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial Eur Heart J 27 2006 178 186
58. V.V. Georgiopoulou, A.P. Kalogeropoulos, G. Giamouzis, S.A. Agha, M.A. Rashad, and S. Waheed et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy Circ Heart Fail 2 2009 90 97
59. A.S. Dhaliwal, A. Bredikis, G. Habib, B.A. Carabello, K. Ramasubbu, and B. Bozkurt Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy Am J Cardiol 102 2008 1356 1360
60. J. Butler, I.S. Anand, M.A. Kuskowski, T. Rector, P. Carson, and J.N. Cohn Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT) Congest Heart Fail 16 2010 191 195
61. G.M. Felker, and C.M. O'Connor Inotropic therapy for heart failure: an evidence-based approach Am Heart J 142 2001 393 401
62. Y. Juilliere, and C. Selton-Suty Digoxin therapy: a persisting interest despite contrary winds Arch Cardiovasc Dis 103 2010 281 284
63. M. Gheorghiade, M. Harinstein, and G. Filippatos Digoxin for the treatment of chronic and acute heart failure syndromes Acute Card Care 11 2009 83 87
64. N. Verma, and V.M. Figueredo Statins in non-ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding Int J Clin Pract 65 2011 1156 1164
65. P. Amarenco, and J. Labreuche Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention Lancet Neurol 8 2009 453 463
66. H. Buchwald, H. Bourdages, C. Campos, P. Nguyen, S. Williams, and J. Boen Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidaemias (POSCH) Surgery 120 1996 672 679
67. T.R. Pedersen, J. Kjekshus, K. Pyorala, A.G. Olsson, T.J. Cook, and T.A. Musliner et al. Effect of simvastatin on ischemic signs and symptoms in the Scandanavian Simvastatin Survival Study (4S) Am J Cardiol 81 1998 333 335
68. G.B. Mancini, S. Baker, J. Bergeron, D. Fitchett, J. Frohlich, and J. Genest et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 2011 635 662
69. R.H. de Smedt, P. Denig, F.M. Haaijer-Ruskamp, and T. Jaarsma Perceived medication adverse effects and coping strategies reported by chronic heart failure patients Int J Clin Pract 63 2009 233 242 [Erratum appears in Int J Clin Pract 2009;63:829]
70. E. Ashton, E. Windebank, M. Skiba, C. Reid, H. Schneider, and F. Rosenfeldt et al. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study Int J Cardiol 146 2011 404 407
71. M. Rauchhaus, A.J. Coats, and S.D. Anker The endotoxin-lipoprotein hypothesis Lancet 356 2000 930 933
72. B.M. Massie, J.F. Collins, S.E. Ammon, P.W. Armstrong, J.G. Cleland, and M. Ezekowitz et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial Circulation 119 2009 1616 1624
73. S. Homma, J.L. Thompson, P.M. Pullicino, B. Levin, R.S. Freudenberger, and J.R. Teerlink et al. Warfarin and aspirin in patients with heart failure and sinus rhythm N Engl J Med 366 2012 1859 1869
74. A.S. Al-Khadra, D.N. Salem, W.M. Rand, J.E. Udelson, J.J. Smith, and M.A. Konstam Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial J Am Coll Cardiol 31 1998 419 425
75. K.N. Nguyen, I. Aursnes, and J. Kjekshus Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) Am J Cardiol 79 1997 115 119